However, in the KEYNOTE-061 phase 3 randomized trial, although pembrolizumab resulted in better safety, it did not significantly improve OS compared with paclitaxel as second-line therapy for patients with advanced GC and PDL1 combined positive score ≥1 (93). This evidence concerns the gene CD274 and gastric cancer.